On World Cancer Research Day, celebrated on September 24, the Vall d’Hebron Barcelona Hospital Campus highlights the research being carried out to better understand the mechanisms underlying the origin and progression of tumours and to transform this knowledge into new diagnostic, prognostic and treatment tools. The aim is to move towards increasingly precise and personalised oncology, helping to improve outcomes and the quality of life of people with cancer.
VHIO: 20 years driving cancer research forward
In the year of its 20th anniversary, VHIO highlights two decades of cancer research. Since its creation in 2006, the centre has helped consolidate a translational research model that brings laboratory discoveries closer to clinical practice and has contributed to some of the advances that have shaped the evolution of precision oncology, from the molecular characterisation of tumours and biomarker validation to the development of molecular pre-screening programmes and one of Europe’s first clinical liquid biopsy pathways.
Over these 20 years, VHIO has participated in more than 9,700 clinical trials and studies, involving more than 21,800 patients, and has contributed to the development of nearly 80 new therapeutic indications that are now used in clinical practice. In parallel, it has strengthened research lines in immunotherapy, cell therapies, early diagnosis and new technologies applied to oncology, while also expanding its international collaboration through more than 300 European projects, networks and consortia. A track record that reflects how research can be translated into new opportunities for people with cancer.
VHIR: ten groups within the Cancer Area
Through its Cancer Area, VHIR addresses the disease from multiple perspectives, with research ranging from the study of the biological mechanisms of tumours to the identification of biomarkers, the development of new drugs and the conduct of clinical trials. During 2025, the ten research groups that make up the area generated 157 publications, participated in 89 research projects and in 88 clinical trials.
Factors such as ageing and circadian rhythms are studied, as well as communication between tumour cells, their proliferation, metastasis and resistance to treatments. Molecular mechanisms are also investigated to identify new therapeutic targets and understand how the relationship between the tumour and its surrounding environment can promote more aggressive and treatment-resistant cancers.
One of the key areas is childhood cancer, with projects aimed at developing more effective and less toxic treatments, combining chemotherapy and immunotherapy, and facilitating access to innovative treatments and clinical trials. This research also addresses a range of adult tumours, including melanoma and prostate, kidney, bladder, ovarian, endometrial, and head and neck cancers. Molecular analysis, biomarkers, proteomics and imaging techniques are helping to advance towards more precise and personalised oncology, while new experimental strategies against resistant tumour cells are also being studied.
VHIR research also incorporates new technologies to improve clinical outcomes and patients’ quality of life.